van den Berge Maarten, Polosa Riccardo, Kerstjens Huib A M, Postma Dirkje S
Department of Pulmonology, University Hospital Groningen, The Netherlands.
J Allergy Clin Immunol. 2004 Oct;114(4):737-46. doi: 10.1016/j.jaci.2004.05.071.
Bronchial hyperresponsiveness is present in virtually all patients with asthma and in more than two thirds of patients with chronic obstructive pulmonary disease. Thus far, methacholine and histamine are usually used to measure bronchial hyperresponsiveness. Both are direct stimuli, because they act directly on airway smooth muscle. Another possible stimulus to measure bronchial hyperresponsiveness is AMP. AMP is an indirect stimulus, because it acts via the release of histamine and other mediators from immunologically primed mast cells. There is increasing interest in the role of AMP as a bronchoconstrictor stimulus because it has been suggested that the concentration of AMP causing the FEV 1 to decrease by 20% (PC 20 AMP) may be used as a noninvasive marker of airway inflammation. The aim of this article was to review the literature assessing AMP's value in asthma and chronic obstructive pulmonary disease.
几乎所有哮喘患者以及超过三分之二的慢性阻塞性肺疾病患者都存在支气管高反应性。到目前为止,通常使用乙酰甲胆碱和组胺来测量支气管高反应性。二者均为直接刺激物,因为它们直接作用于气道平滑肌。另一种可用于测量支气管高反应性的可能刺激物是腺苷一磷酸(AMP)。AMP是一种间接刺激物,因为它通过免疫致敏的肥大细胞释放组胺和其他介质来发挥作用。由于有人提出使第一秒用力呼气容积(FEV₁)下降20%的AMP浓度(PC₂₀ AMP)可作为气道炎症的无创标志物,因此人们对AMP作为支气管收缩刺激物的作用越来越感兴趣。本文的目的是综述评估AMP在哮喘和慢性阻塞性肺疾病中价值的文献。